

## PLACID TRIAL Mortality Assessment

### 1 Supplementary

### 2 Flowchart for the study protocol

3

4

5

6

7

8


9

10

11

12

13



14 The Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease  
15 (PLACID) Trial recruited 464 eligible patients for the study. The primary outcome at 28 days was  
16 not available for two patients who were lost to follow-up after discharge; nine patients withdrew  
17 consent after randomisation and two patients did not receive the intervention after  
18 randomisation as a matched donor was not available. The cohort with known outcome at 28 days  
19 thus comprised of 451 patients out of whom 386 survived and 65 died.

20